PDR-001 (Prodegrade)

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NamePDR-001 (Prodegrade)

Drug Alias NamePDR-001

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionSynuclein alpha degradersProteolysis

TargetsSynuclein alpha

Therapy Area/IndicationsParkinson DiseaseLewy Body DiseaseMultiple System Atrophy

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaClinical

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesPurui (Shanghai) Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsParkinson DiseaseLewy Body DiseaseMultiple System Atrophy

Inactive IndicationsN/A

Other Information

ATC CodeN/A